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Abstract.  The regulation of fibronectin (FN) biosyn- 
thesis by dexamethasone (a synthetic glucocorticoid), 
forskolin (an activator of adenylate cyclase), and trans- 
forming growth factor 13 (TGF-[I) was examined in six 
human cell lines.  Dexamethasone treatment produced 
the largest increase in FN biosynthesis in the fibrosar- 
coma cell line, HT-1080  ('045-fold).  This seems to re- 
sult from a dexamethasone-mediated increase in FN 
mRNA stability which increases the message half-life 
from "011 to 26 h. The relative instability of FN mRNA 
in the fibrosarcoma (t,~ 11  h) compared to normal 
fibroblasts (70 h) appears to result from the particular 
transformed phenotype of the HT-1080 cells. Forskolin 
and TGF-[I increase the rate of FN gene transcription 
in most of the cell lines. These effects (four- to six- 
fold) occur rapidly and do not require protein synthe- 
sis in the responsive cell lines which include normal 
fibroblasts.  However, in the fibrosarcoma (HT-1080),  a 
surprisingly large induction (20-30-fold)  is observed 
and this induction is different from that in the normal 
fibroblasts and the other cell lines in that both protein 
synthesis and a  lag period are required.  Synergism is 
seen with dexamethasone and either forskolin or TGF- 
13 in HT-1080 cells increasing the rate of FN biosyn- 
thesis "0200-fold to a  level similar to normal fibro- 
blasts. This seems to result from a  combination of FN 
mRNA stabilization (dexamethasone) and increased 
transcription (forskolin and TGF-13). 
F 
IBRONECTINS (FNs) t are a group of large glycopro- 
teins found both as an insoluble form (cellular FN) in 
extracellular matrices and in a soluble form (plasma 
FN)  in plasma.  They contain two subunits of "0 230  and 
250 kD that are cross-linked by disulfide bonding (reviewed 
by Ruoslahti et al., 1981; Hynes and Yamada,  1982; Yamada, 
1983).  Up to 20 different FN polypeptides can be generated 
by differential splicing of the mRNA transcribed from a sin- 
gle gene (Kornblihtt et al.,  1985;  Gutman and Kornblihtt, 
1987; Schwarzbauer et al., 1987).  Such differential splicing 
seems to account for both the difference between the cellu- 
lar and plasma forms and the difference between the two 
subunits (Atherton and Hynes, 1981; Kornblihtt et al., 1985; 
Schwarzbauer et al.,  1987). 
At the amino acid level, FN is composed of three different 
types of internal repeats designated I, II, and III which con- 
tain  ,040,  60,  and  90  amino  acid  residues,  respectively 
(Skorstengaard et al.,  1982;  Petersen et al.,  1983;  Patel et 
al., 1987). The FN molecule is arranged in a series of globu- 
lar domains which can bind independently to a number of 
different molecules such as heparin, DNA, collagen, actin, 
and fibrin, as well as to bacteria (Yamada,  1983) and to the 
1. Abbreviations  used in this paper:  CAT, chloramphenicol acetyltransfer- 
ase; CRE, cAMP response element; IBMX, 3-isobutyl-l-methyl-xanthine; 
FN, fibronectin; LTR, long terminal repeat; MMTV, mouse mammary tu- 
mor virus; TGF-13, transforming growth factor 13. 
surface  of cells  through  a  dimeric  membrane-bound FN 
receptor (Pytela et al.,  1985;  Hynes,  1987).  The primary 
role of FN appears to be in cellular adhesion which is impor- 
tant in a variety of functions such as cellular differentiation 
and migration, wound healing, blood coagulation, and tumor 
metastatis (Yamada,  1983). It is of interest to determine how 
FN biosynthesis is regulated to better understand its role in 
each of these processes. 
The expression of FN is greatly inhibited by neoplastic 
transformation in most of the cases examined (Vaheri et al., 
1976; Olden and Yamada,  1977; Yamada et al., 1977; Hynes 
et al.,  1978; Vaheri and Mosher, 1978; Fagan et al.,  1981). 
This inhibition can be reproduced in cell culture by transfec- 
tion of certain oncogenes (Levinson et al.,  1975; Setoyama 
et al., 1985). It has been demonstrated that this inhibition of 
FN expression results from both a depression of transcrip- 
tion and a decrease in FN half-life (Olden and Yamada,  1977; 
Tyagi et al., 1983). However, the mechanism of  this suppres- 
sion has not been defined. The loss of FN from the cell sur- 
face after transformation results in decreased cellular adhe- 
sion which has been correlated with increased metastasis of 
tumor cells (reviewed in Roos,  1984). 
The synthesis of FN is induced by glucocorticoids (Furcht 
et al.,  1979a, b; Oliver et al.,  1983;  Nimmer et al.,  1987) 
and by transforming growth factor I~ (TGF-13) (Sporn et al., 
1983; Ignotz and Massague, 1985; Roberts et al., 1986; Ig- 
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coids have a well-known role in response to stress, suggest- 
ing that they may provide an early mechanism of inducing 
FN in processes such as wound healing. TGF-13  seems to play 
a  role  in  cellular differentiation (reviewed in  Massague, 
1985; Sporn et al., 1986). It is also well known that extracel- 
lular matrix plays an important role in determining cellular 
morphology and behavior. Therefore, the effect of TGF-13 on 
cellular differentiation may be mediated through its regula- 
tion of extracellular matrix components. 
In an effort to better understand how FN synthesis is con- 
trolled, we have recently cloned the promoter region of the 
human gene (Dean et al., 1987). Studies on the nature of this 
promoter should provide insight into how the gene is regu- 
lated. In this paper, we examine the mechanisms of FN in- 
duction by both TGF-13 and glucocorticoids in different hu- 
man cell lines. We also show that FN is responsive to cAMP 
and analyze the mechanisms involved. 
Materials and Methods 
Cell Culture and DNA Transfection 
All cells were grown in DME in the presence or absence of 10%  FCS at 
37°C as described previously (Oliver et al.,  1983). The HT-1080 cell line 
(Rasheed et al., 1974) was subcloned and a clone designated HT- 1080C was 
used (Oliver et al.,  1983). Drugs were added to cell cultures at the concen- 
trations and for the time periods indicated in the figure legends. Forskolin 
was from Calbiochem-Behring Corp., La Jolla, CA, and TGF-I3 was from 
R  and  D  Systems, Inc.,  Minneapolis,  MN,  or was a  gift from Michael 
Sporn, National Cancer Institute, Bethesda, MD. Cells were transfected by 
the calcium phosphate method as described previously (Knoll et al., 1983). 
Approximately 15 ~g of plasmid was used to transfect each  10-cm plate 
which was ",,30 % confluent. 5 I.tg of the plasmid RSV-fi-Gal (Edlund et al., 
1985) was cotransfected with each plasmid. Assays for [3-galactosidase (Ed- 
lund et al.,  1985)  were then used to standardize each of the transfections. 
Approximately 100 I.tg of protein was used for 13-galactosidase  assays in the 
HT-1080 and WI38 cell lines, while 20 p.g was used from JEG-3 cells. Un- 
der these conditions, 5-6 h were usually required for a color reaction to oc- 
cur in HT-1080 and WI38 cells but only '~20 min was required in JEG-3 
cells. Values for nontransfected cells were used as a control.  Drugs were 
added to the transfected cells as indicated in the figure legends and the cells 
were harvested after 48 h. Chloramphenicol acetyltransferase (CAT) assays 
were done as described previously (Gorman,  1985)  using 50 ~tg of protein 
and a  l-h reaction time for both JEG-3 and HT-1080 cells. W138 cells re- 
quired a 6-h reaction time. 
Plasmid Construction 
The plasmid pFN-CAT contains a pst I fragment of the human FN gene from 
+69 to ",,-1.6 kb (Dean et al.,  1987). The 5' end of this fragment contains 
'x,l.1 kb of lambda DNA from the original charon 28 vector. This pst I frag- 
ment was blunt ended with T4-DNA polymerase (Maniatis et al.,  1982a) 
and subcloned into the sma I site of pSVOCAT (sma I). Orientation was de- 
termined by restriction digestion.  The plasmid pRSV-[3-Gal  was from P. 
Mellon (The Salk Institute for Biological Studies, San Diego, CA) and the 
plasmid pMMTV-CAT was from R. Evans (The Salk Institute for Biological 
Studies). 
RNA Isolation and Analysis 
Total  RNA was isolated from cell monolayers by the guanidinium thiocya- 
nate method (Maniatis et al.,  1982b).  S-1 analysis was done as described 
previously with 5'-32p-labeled  probes (Dean et al., 1987) and ,,,50 I.tg of to- 
tal RNA was used for each analysis. As a control, equal amounts of RNA 
used for S-1 analysis were slot blotted and probed with a constitutively ex- 
pressed gene, CHO-B (Harpold et al.,  1979). The CHO-B gene was not 
responsive to any of the drugs tested (unpublished data). The inhibition of 
protein synthesis by cycloheximide was determined by incubating cells in 
various concentrations of cycloheximide for  1 h after which time the rate 
of incorporation of [35S]methionine  into protein was determined. The effect 
of cycloheximide on protein synthesis was rapid, occurring in 1 h or less. 
To examine the effect of cycloheximide on dexamethasone induction of the 
mouse mammary tumor virus promoter (MMTV), the plasmid pMMTV- 
CAT (20  Ixg) was transfected into  10-cm dishes of HT-1080 cells as de- 
scribed above. Dexamethasone and cycloheximide were added after 18 h and 
incubation was continued for an additional 36 h. Total RNA was isolated 
from treated or untreated cells and 30 Ilg was slot blotted onto hybond-N 
membrane (Amersham Corp., Arlington Heights, IL). The membrane was 
then hybridized, as described previously (Dean et al.,  1987), to pMMTV- 
CAT labeled with 32p by nick translation (Rigby et al.,  1977). 
In Vitro Transcription in Isolated Nuclei 
In vitro transcription assays in isolated nuclei were done essentially as de- 
scribed elsewhere (Greenberg and Ziff,  1984).  Cells were  incubated for 
48 h in the presence or absence of drugs and ~1  ×  10  7 cells were used for 
each assay. Cells were washed three times with ice cold PBS and lysed in 
a  buffer containing 0.5%  NP-40 (Sigma Chemical Co., St.  Louis, MO). 
Nuclei were collected after centrifugation at 600 g  for 5  min and gently 
resuspended in 100 Ixl of 50 mM Tris-HCl, pH 8.3, 5 mM MgCI2, 0.1 mM 
EDTA with 40% glycerol. The nuclei were then frozen at -100°C for later 
use. For the transcription experiments, nuclei were thawed and mixed with 
100 ~tl of reaction buffer (10 mM Tris-HCl, pH 8.0, 5 mM MgCI2, 300 mM 
KCI, 1 mM each of ATP, CTP, and GTP, and 200 ktCi of [¢t32p]UTP, >600 
Ci/mmol; Amersham  Corp.) and incubated at 30°C for 30 min. The mixture 
was then treated with 75 U of RNase-free DNase (Promega Biotechnologies, 
Madison, WI) for 10 rain at room temperature and phenol/chloroform ex- 
tracted two times. RNA was then ethanol precipitated three times in the 
presence of 3.75 M ammonium acetate. Incorporation of 32p into RNA was 
measured by TCA precipitation. Approximately 2-5  ×  l0  7 cpm was incor- 
porated in 1 x  107 cell nuclei. The [32p]RNA  was then hybridized to 2 I.tg 
of the plasmid pgHF 3.7 (Dean et al.,  1987) which contains a  1-kb piece 
of the human FN gene or to 2 p.g of the control vector pGEM-4 (Promega 
Biotechnologies) immobilized to nitrocellulose by slot blotting. This frag- 
ment does not contain any repeated sequences as analyzed by Southern blot 
hybridization to human genomic DNA (data not shown). Equal amounts of 
cpm (see figure legend) were hybridized to the filters in  1 ml of solution 
as  described  (Dean  et  al.,  1987).  The  in  vitro  transcription  assay was 
repeated four times for each drug. 
Metabolic Labeling and lmmunoprecipitation 
For metabolic labeling, each 60-mm dish of cells (near confluency) was in- 
cubated for 90 min in 0.4 rnl of DME (minus methionine) containing 150 
I.tCi/ml  of [35S]methionine (600-1,400 Ci/mmol;  New England Nuclear, 
Boston, MA). An equal volume of 2× cell lysing buffer (40 mM Tris-HCl, 
pH 8.8, 4%  deoxycholate, 4  mM phenylmethylsulfonyl fuoride [PMSF], 
4  mM EDTA, 4  mM iodoacetic acid, 2  mM N-ethyl maleimide, and  1% 
NP-40) was added, the lysate was sheared through a syringe needle and cen- 
trifuged at  10,000 g  for  10 min at 4°C.  Equal cpm, determined by TCA 
precipitation, were incubated with an excess of goat anti-human FN IgG 
followed by rabbit anti-goat IgG (both antisera were from Cappel Laborato- 
ries, Cochranville, PA). Precipitated proteins were washed three times in 
20 mM Tris-HCI, pH 8.8, 0.5% deoxycholate, 50 mM NaC1, 2 mM PMSE 
2 mM EDTA, 0.5% NP-40, and subjected to electrophoresis on SDS-poly- 
acrylamide gels as described previously (Oliver et al.,  1983). 
RNA Pulse-Chase 
FN mRNA decay experiments were done as described elsewhere (Paek and 
Axel, 1987). HT-1080 cells were treated with 2  ×  10  -7 M dexamethasone 
for 48  h  before  pulse labeling.  Cells were  treated  with  200  I~Ci/ml  of 
[5-3Hluridine  (16  Ci/mmol) for  5  h  in DME  and  10%  FCS.  After this 
time, the labeling media was removed and the cells were rinsed with DME 
three times and incubated for various times in the presence of 5 mM uridine. 
RNA was isolated as described above and ethanol l~recipitated  three times 
in the presence of 3.75 M ammonium acetate. Incorporation of [3H]uridine 
into RNA was quantitated by TCA precipitation. [3H]RNA was hybridized 
to the plasmid, pgHF3.7 (Dean et al., 1987) or to the vector pGEM-4 bound 
to nitrocellulose filters. Hybridization was done in 200 I11 as described pre- 
viously (Dean et al., 1987). Filters were treated with 40 mM NaOH for 2 h 
and the eluate was counted in a scintillation counter. The background cpm 
bound to the pGEM-4 filters was substracted from the cpm on the pgHF3.2 
filters at each time point. Background ranged from '~10  -5 to 10  -6 of input 
The Journal of Cell Biology, Volume 106,  1988  2160 Figure 1. Effect of dexametha- 
sone, forskolin, and TGF-13  on 
the rate of FN biosynthesis in 
the  human  fibrosarcoma  cell 
line,  HT-1080.  Cells  were 
treated with drugs for the indi- 
cated times. Incubation in the 
presence  of  drug  combina- 
tions was for 48 h. After drug 
treatment,  cells  were labeled 
with  [3SS]methionine and FN 
was  immunoprecipitated  and 
subjected to electrophoresis on 
an  SDS-polyacrylamide  gel 
(see Materials and Methods). 
Dex,  dexamethasone  (2  × 
10  -7  M);  IBMX, 3-isobutyl- 
1-methyl-xanthine (2  x  10-4 
M);  T,  TGF-I~ (500  pM);  F,, 
forskolin (1.8  x  10  -5 M). 
cpm. The points shown in Fig.  6 B are the average of two independent ex- 
periments each being representative  of the average. 
Results 
Regulation of FN by Glucocorticoids 
Six human cell lines have been used in this  study:  the  fi- 
brosarcoma, HT-1080 (Rasheed et al.,  1974;  Oliver et al., 
1983);  JEG-3,  a  choriocarcinoma  (Kohler  and  Bridson, 
1971); TE671, a medulloblastoma (McAllister et al.,  1977); 
HeLa Bu25, a cervical carcinoma (Kit et al.,  1966); and two 
normal fibroblasts, from lung (WI38) and from foreskin (FS- 
1).  All of the cells in the study exhibit a basal level of FN 
expression although this level varies greatly. Normal fibro- 
blasts exhibit high basal levels of FN (0.3 % of total protein) 
while the transformed cell lines all had much lower levels: 
JEG-3 (0.01%),  TE671 (0.002 %), HeLa Bu25 (0.008 %), and 
HT-1080 (0.004%).  It is of particular interest that the level 
of FN is so low in the fibrosarcoma cell line compared to nor- 
mal fibroblasts. 
We have demonstrated previously that the rate of FN bio- 
synthesis is increased by the synthetic glucocorticoid, dexa- 
methasone,  in  the  human fibrosarcoma cell  line  HT-1080 
(Oliver et al.,  1983).  The kinetics of this response is shown 
in Fig.  1.  Quantitative estimates of increases in the rate of 
FN biosynthesis were obtained by cutting the FN band from 
SDS-polyacrylamide gels and counting the cpm in the bands 
(see Table I). The rate of FN biosynthesis is increased '~45- 
fold, however 48 h is required for full induction. Dexametha- 
sone  treatment  of  other  cell  lines  which  synthesize  FN 
results  in  varying levels of FN  induction.  After 48  h,  no 
dexamethasone induction is seen in JEG-3 or in TE671 cells 
and only a  small induction is seen in WI38 (less than two- 
fold), HeLa Bu25  cells (threefold),  and FS-1  (twofold). 
Additional studies to determine the mode of action of dexa- 
methasone on FN biosynthesis were carried out in HT-1080 
cells since FN levels in these cells are the most responsive. 
The morphology of HT-1080 is not drastically changed by 
dexamethasone (Fig.  2)  and this  steroid has no detectable 
effect on the growth of these cells (Fig.  3).  There was also 
no apparent effect of dexamethasone on the morphology or 
growth rate of the other cell lines (data not shown). 
To determine  if dexamethasone  induction  occurs  at the 
level ofFN mRNA in HT- 1080 cells, an S-1 nuclease protec- 
tion assay was used. The results demonstrate that dexametha- 
sone  increases  the  level of accumulated  FN  mRNA  tran- 
scribed from the FN promoter (Fig. 4). The kinetics of FN 
induction  by dexamethasone (Fig.  1)  seem to be relatively 
slow  when  compared to  induction  of the  metallothionein 
gene or the MMTV long terminal repeat (LTR) which are 
known to be induced directly by glucocorticoids and do not 
Table I. Induction of  Fibronectin  in Human Cell Lines 
Drugs  HT- 1080  JEG-3  TE671  W138  HeLa  FS- 1 
Dex  45.0  1.1  0.7  1.6  3.2  1.8 
Forskolin  27.5  4.7  0.8  1.1  0.3  0.5 
TGF-I~  22.0  1.1  2.2  6.7  1.1  3.7 
Dex  +  forskolin  251  3.3  2.9  2.4  2.1  0.6 
Dex  +  TGF-13  171  1.1  1.1  8.5  11.0  3.3 
Forskolin  +  TGF-13  63  5.1  1.7  4.3  0.7  1.7 
Dex  +  forskolin +  TGF-I~  184  4.9  2.4  5.4  5.1  2.2 
Quantitation of the rate of FN biosynthesis after treatment of various  human cells with dexamethasone  (Dex), forskolin,  and TGF-13. The numbers correspond 
to inductions in the rate of FN biosynthesis and were obtained by cutting the FN-specific band from the gel in Fig.  1 (the 48-h time point) and from similar gels 
of the other cell lines (photographs of the autoradiograms  were submitted to reviewers).  Inductions were determined  by dividing the cpm in a specific band by 
the cpm in the band from untreated cells. 
Dean et al. Regulation of Fibronectin Biosynthesis  2161 Figure 2.  Phase-contrast photomicrographs  of HT-1080 cells in the presence of dexamethasone,  forskolin and IBMX, or TGF-13. Cells 
were treated with the various drugs for 48 h (see Fig.  1 for drug concentrations) and photographed with Kodak plus-X pan film using a 
Zeiss inverted microscope with phase-contrast  optics. Bars,  25 lam. 
require protein synthesis for induction (Yamamoto and AI- 
berts, 1976). This suggested that dexamethasone induction of 
FN might occur through an indirect mechanism. Other pro- 
teins that are indirectly induced by glucocorticoids are ctt-acid 
glycoprotein (Baumann and Maquat,  1986)  and a2u-globu- 
lin (Addison and Kurtz,  1986). To determine if this was the 
case, HT-1080 cells were incubated in the presence of cyclo- 
heximide to inhibit protein synthesis and the effect on dexa- 
methasone induction of FN mRNA was analyzed (Fig.  5). 
As a control, a plasmid containing the MMTV LTR linked 
to the CAT gene was transfected into the HT-1080 cells. The 
MMTV LTR is directly inducible by dexamethasone and this 
induction should not require protein synthesis.  The results 
confirm that dexamethasone is able to induce expression of 
CAT mRNA from the MMTV LTR in the presence of cyclo- 
heximide; however, under the same conditions, induction of 
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Figure 3. Growth rate of the HT-1080 cell line in the presence of 
dexamethasone  (o),  forskolin  and  IBMX  (A),  and  TGF-13 (zx). 
Equal numbers of HT-1080 cells were aliquoted into 60-mm dishes 
and grown for 3 d in the presence or absence of drugs (see Fig. 1 
for concentrations)  to near confluency. Cells were removed from 
dishes with trypsin-EDTA and counted with a Coulter counter. The 
data shown is an average of two experiments.  (o) Control. 
FN mRNA was blocked demonstrating that protein synthesis 
is  required  for dexamethasone  induction  of FN  (Fig.  5). 
Similar effects were observed if cycloheximide was added at 
the same time as dexamethasone or 2 h before or after dexa- 
methasone addition  (data not shown). 
To determine if dexamethasone induction of FN is due to 
an increase in the rate of transcription of the FN gene,  in 
vitro transcription  in  isolated  nuclei  was performed.  The 
results, shown in Fig. 6 A, illustrate that dexamethasone does 
not stimulate the rate of FN transcription in HT-1080 cells. 
Since the level of FN mRNA is increased but the rate of tran- 
scription  is  unchanged,  dexamethasone must increase  the 
stability of FN mRNA. When the FN promoter is fused to 
the bacterial CAT gene and transfected into various human 
cell lines, no dexamethasone induction is observed in any of 
the cells. The results for HT-1080 and WI38 cells are shown 
in Fig. 7; the results for the other cell lines are not shown. 
This supports the hypothesis that the effect of dexamethasone 
on FN expression is not at the level of transcription. 
A pulse-chase experiment was used to measure the effect 
of dexamethasone on the decay rate of FN mRNA in HT- 
1080 cells. Cells were incubated for 48 h in the presence or 
absence of dexamethasone and labeled for 5 h with [3H]uri- 
dine as described previously (Paek and Axel,  1987).  The 
time course of [3H]FN mRNA decay was measured by hy- 
bridization to a  plasmid containing  a  fragment of the  FN 
gene bound to filters. Initially, the levels of pulse-labeled FN 
mRNA were similar in HT-1080 and WI38 cells and were 
unaffected by dexamethasone in HT-1080 cells. This obser- 
vation is in  agreement with our measurements of rates of 
transcription (Fig. 6 A) in which no effect of dexamethasone 
was observed.  However, FN mRNA decayed more rapidly 
in the untreated HT-1080 cells; this decay suggests that dexa- 
methasone treatment increases the stability of FN mRNA in 
these cells (Fig. 6 B). The half-life of FN mRNA is estimated 
to be 11 h in untreated HT-1080 cells and 26 h in dexametha- 
sone-treated cells.  The half-life in WI38 cells is '~70 h. 
TGF-~ Can Increase FN Levels by Two 
Different Mechanisms 
The effect of TGF-I3 on the rate of FN biosynthesis was first 
examined in the fibrosarcoma cell line, HT-1080. A concen- 
tration of 500 pM was chosen for the experiments. Increasing 
this concentration to 1 nM did not significantly increase the 
rate of FN biosynthesis; however, lowering the concentration 
to  50 pM  eliminated most of the  FN  induction  (data  not 
shown). 
The effect of TGF-13 on FN biosynthesis is shown in Fig. 
1 and Table I. In HT-1080 cells,  FN is induced by TGF-13 
'~22-fold (see Table I). In WI38 cells the induction is seven- 
fold, in FS-1 fourfold, and in TE671 about twofold. No sig- 
nificant  induction  is  seen  in  JEG-3  or  HeLa Bu25  cells. 
Since  HT-1080  cells  exhibited  the  largest  induction  with 
TGF-[3, these cells were used to study the effect of this drug 
on morphology and growth. Fig. 2 shows that TGF-13 causes 
HT-1080 to grow as spherical cells which form aggregates 
that are weakly attached to the culture  dish.  No effect of 
TGF-13 on the growth rate of HT-1080 cells was observed 
(Fig. 3) and no striking effects on the morphology or growth 
rate in the other cell lines was apparent. 
The kinetics of TGF-13 induction in HT-1080 cells appears 
to be biphasic (Fig.  8).  A  relatively small induction of ap- 
proximately sixfold occurs in the first 24 h. After 24 h, the 
induction increases sharply to ,,o30-fold;  however, in WI38 
cells induction is apparent by 5 h and increases in a linear 
fashion with time up to between 24 and 48 h  (Fig.  8). 
S-1 nuclease protection experiments illustrate that TGF-13 
treatment increases the amount of FN mRNA in both HT- 
1080 and WI38 cells rather than increasing the rate of trans- 
lation (Fig. 5). When protein synthesis is inhibited with cy- 
cloheximide, TGF-I~ induction of FN mRNA is substantially 
blocked in HT-1080 cells (Fig. 5); however, no effect of cy- 
cloheximide is observed in WI38 cells (Fig.  5).  This indi- 
cates that the mechanism of TGF-13 induction differs in the 
fibrosarcoma (HT-1080) and the normal fibroblast. 
When the FN-CAT construct is transfected into both HT- 
1080 and WI38 cells,  a three- to sixfold induction of CAT 
synthesis is observed with TGF-13 in both cells (Fig. 7). This 
induction is similar in magnitude to that observed for FN and 
FN mRNA in WI38, but is smaller than the induction ob- 
served in HT-1080 ('~20-fold). Therefore, the full effect of 
TGF-[3 on the level of FN in WI38 cells can be accounted 
for by increased transcription; however, only a portion of the 
TGF-13 induction of FN and FN mRNA in HT-1080 can be 
accounted for by an increased transcription rate, suggesting 
the possibility that the remainder of the induction could re- 
sult from FN mRNA stabilization as suggested above with 
dexamethasone. 
As mentioned above, the kinetics of TGF-13 induction  in 
HT-1080 appears to be biphasic.  The early induction  be- 
tween 6 and 24 h is about sixfold and is similar to the level of 
induction observed in both in vitro transcription in isolated 
nuclei and in transfection experiments. It is, therefore, possi- 
ble that this early event corresponds to an increase in gene 
transcription, while the second phase of induction observed 
after 24 h could involve FN mRNA stabilization; however, 
more experiments are required to confirm this. 
We have also examined the effect of serum on the rate of 
FN biosynthesis in HT-1080 cells. The basal level of FN ex- 
pression is stimulated two- to threefold in the presence of 
10% serum; however, induction by TGF-13 decreases approx- 
imately two- to threefold in the presence of serum (Fig. 9). 
Dean  et al. Regulation of Fibronectin Biosynthesis  2163 Figure 4.  Effect of dexamethasone (Dex), forskolin, and TGF-13 on FN mRNA levels in HT-1080 cells. An S-1  nuclease assay was used 
to quantitate the amount of FN mRNA. A 5'32P-labeled DNA probe was used to map the 5' end of the FN mRNA as described previously 
(Dean et al.,  1987).  Equal amounts of total RNA (,x,50  ktg) were used for each reaction. A  schematic diagram of the 5' end of the FN 
gene and S-1  probe is shown at the bottom of the figure.  The left-hand lane is a  size standard of 32p-labeled pBR322  cut with Msp I. 
The Journal of Cell Biology, Volume 106, 1988  2164 Figure 5. (A) S1 analyses.  The effect of cycloheximide  on the induction of FN mRNA by dexamethasone  (Dex),  forskolin,  and TGF-13 in 
HT-1080,  WI38, and JEG-3 (JEG) cells.  An S-I nuclease analysis  was used to quantitate  FN mRNA levels (see Fig. 4).  Equal amounts 
of total RNA (•50  gg) were used in each experiment.  Cells were incubated  for 40 h in the presence or absence of cycloheximide (Cyclo) 
(20 I~g/ml, HT-1080; 16 ~tg/ml, JEG-3; 4 gg/ml, WI38) and the various drugs (see Fig. 1 for concentrations). (B) Slot blots of MMTV-CAT 
RNA. Effect of cycloheximide  on dexamethasone  induction of a transfected  MMTV promoter.  HT-1080 cells  were transfected  with the 
plasmid pMMTV-CAT, which contains the MMTV promoter fused to the bacterial  CAT gene, and incubated  in the presence of cyclohexi- 
mide (20 ~tg/ml) with or without 2  x  10  -7 M dexamethasone  for 36 h as described in Materials  and Methods.  RNA was isolated  and 30 
gg was immobilized onto a nylon membrane by slot blotting.  The membrane was then hybridized  to a 32p-labeled pMMTV-CAT probe. 
(C) Cycloheximide sensitivities.  The graphs show the effect of cycloheximide  concentration on protein synthesis  in the various  cells and 
were used to determine the amount of cycioheximide  required  to inhibit  at least 90% of protein synthesis  (see Materials  and Methods). 
Effect of  cAMP on FN Biosynthesis 
The effect of  increased cAMP levels on the rate of  FN biosyn- 
thesis  was examined  initially  in the HT-1080 cell line.  In- 
duction was observed with dibutryl cAMP, 8-bromo cAMP, 
forskolin (an activator of adenylate cyclase), and the phos- 
phodiesterase inhibitor,  3-isobutyl-l-methyl-xanthine 0BMX), 
as well as with various combinations of these drugs (data not 
shown). The minimal amount of dibutryl cAMP required for 
induction was  1  ×  10  -a M;  1  x  10  -5 M  was not effective. 
The level of forskolin chosen for induction studies  was  1.8 
×  10  -5 M  in combination with 2  x  10  -4 M  IBMX. A three- 
fold  increase  or  decrease  in  these  concentrations  had  no 
effect on induction (data  not shown).  This  combination of 
forskolin and IBMX was then tested on various cell lines. 
The effect of forskolin and IBMX on the growth and mor- 
phology of HT-1080  cells  was  examined  since these  cells 
show the greatest ellect of this drug on FN biosynthesis. The 
growth rate in the presence of forskolin was substantially de- 
creased (Fig. 3) although there was no significant change in 
the rate of protein biosynthesis (data not shown).  The mor- 
phology of the cells was markedly altered in the presence of 
forskolin; the cells became elongated with numerous projec- 
tions (Fig.  2). 
The kinetics of the forskolin effect in HT-1080 cells indi- 
cate that a large increase (,~28-fold) in the rate of FN biosyn- 
thesis occurs between 24 and 48 h of treatment (Figs.  1 and 
10). As illustrated with TGF-I~, S1 nuclease analysis demon- 
strates that forskolin increases the amount of FN mRNA in 
HT-1080 cells rather than increasing the rate of translation 
(Fig.  4).  However, induction of FN mRNA by forskolin in 
HT-1080 cells is blocked by cycloheximide, thus indicating 
an indirect effect which requires protein synthesis  (Fig.  5). 
Dean et al. Regulation of Fibronectin Biosynthesis  2165 Figure 6. Measurements  of the rate of FN gene transcription and the time course of FN mRNA decay. (A) In vitro transcription  in isolated 
nuclei (see Materials  and Methods).  Cells were treated with drugs for 48 h (see Fig.  1 for concentrations), nuclei were isolated,  and RNA 
was labeled  with  [32p]UTP. The labeled  RNA was then hybridized to the plasmid PgHF3.7 which contains  a genomic DNA fragment of 
the human FN gene (Dean et al.,  1987) or to the control vector pGEM-4 immobilized  onto a nitrocellulose  filter by slot blotting.  1 x 
107 cpm of 32p-labeled RNA was hybridized to the filters in a l-ml volume in the bottom experiment.  In the top experiment,  more 3~p-labeled 
RNA (5  x  108 cpm/ml) was used in the hybridization in order to better detect transcription in the untreated  and dexamethasone-treated 
cells. Dex, dexamethasone;  Forsk, forskolin.  (B) Time course of FN mRNA decay. Cells were labeled  for 5 h with  [5-3H]uridine as de- 
scribed  in Materials  and  Methods.  Incubation was continued with 5 mM uridine  for various  times  after which [3H]RNA was isolated 
and [3H]FN mRNA quantitated  by hybridization to an excess of an FN gene fragment bound to nitrocellulose  filters. Nonspecific  hybrid- 
ization  to the vector (pGEM-4) was subtracted  from each point.  The data are presented  as parts per million  (ppm). Where indicated, 
cells  were  incubated  in 2  x  10  -7 M dexamethasone  for 48 h before labeling  which was continued until  [3H]RNA isolation.  WI38 (o); 
HT-1080 (zx); HT-1080 treated  with dexamethasone  (<3). 
The mechanism of this induction appears to be complex. In 
vitro transcription in isolated nuclei (Fig. 6) and transfection 
experiments (Fig. 8) indicate a transcriptional effect of only 
four- to sixfold,  which is less than the *28-fold induction 
seen at the protein and mRNA levels, suggesting the possibil- 
ity that the induction also involves FN mRNA stabilization 
as was suggested for TGF-13 in these cells. 
In JEG-3,  TE671,  and WI38 cells,  forskolin induces the 
rate of FN biosynthesis rapidly; the effect is maximal at 24 h 
and decreases thereafter (see Table I, Fig.  10; other data not 
shown).  The largest response to forskolin is seen in JEG-3 
cells  (approximately  sixfold).  In  some  of  the  cell  lines 
(TE671, HeLa Bu25, WI38, and FS-1) treatment with forsko- 
lin for 48 h results in rates of FN biosynthesis that are even 
lower than basal levels (Table I). This effect is also seen when 
the FN-CAT construct is transfected into WI38 (Fig.  7) or 
HeLa Bu25 (data not shown) cells which are then treated for 
48 h with forskolin. The decrease in FN levels after 24 h of 
forskolin  treatment  appears  to  be  a  feedback  mechanism 
rather than due to degradation of forskolin since addition of 
more forskolin at 24-h intervals during the incubation had no 
effect (data not shown).  Transfection assays in JEG-3 cells 
suggest that the  forskolin effect in these cells  is  transcrip- 
tional (Fig. 7).  The amount of induction of FN (Table I and 
Fig. 9) and FN mRNA (Fig. 5) by forskolin is similar in mag- 
nitude  to  induction  observed  in  transfection  experiments 
(Fig. 7) suggesting that the forskolin effect in JEG-3 cells can 
be accounted for entirely by increased transcription.  Unlike 
HT-1080 cells, protein synthesis is not required for forskolin 
induction of FN mRNA in JEG-3. The mechanism of forsko- 
lin induction of FN is then different in HT-1080 compared 
to the other cell lines, as was the case with TGF-I~ induction 
discussed above. 
Synergism between Dexamethasone and TGF-~ 
or Forskolin 
In HT-1080 cells, the combination of TGF-13 and dexametha- 
sone, or forskolin and dexamethasone, results in a very large 
increase in the rate of FN biosynthesis ("~200-fold) (Fig.  1 
and  Table  I).  This  synergistic  effect  is  three-  to  fourfold 
greater than one would expect from an additive effect.  No 
synergism is observed with the combination of TGF-13 and 
forskolin. Synergism is also observed with TGF-I~ and dexa- 
methasone in HeLa Bu25 cells (~ll-fold induction) but not 
with forskolin and dexamethasone.  No synergism is seen in 
WI38, FS-1,  or JEG-3 cells  (Table I).  In TE671,  induction 
is observed with the combination of forskolin and dexameth- 
asone (approximately fourfold) even though no induction is 
observed with dexamethasone or forskolin alone. 
It seems likely that the synergism in FN induction is due, 
at  least  in  part,  to  dexamethasone  acting  to  stabilize  FN 
mRNA, while TGF-I~ and forskolin stimulate transcription, 
since  addition  of dexamethasone  to  TGf-I]-  or  forskolin- 
treated cells does not further increase the transcription rate 
of the FN gene (Fig. 6 A). The effect may be more complex 
than this based on the action of dexamethasone and forskolin 
on TE671 cells.  While neither of these drugs alone induces 
The Journal of Cell Biology, Volume 106, 1988  2166 Figure 7. Effect of dexamethasone, forskolin, and TGF-13 on expression of CAT from a transfected plasmid (pFN-CAT) containing the FN 
gene promoter fused to the CAT gene. Transfections were done as described  in Materials and Methods. In each transfection, the plasmid 
pRSV-13-gal was included and I~-galactosidase assays were used to normalize the amount of extract used for CAT assays. HT-I080 and 
WI38 cells were treated with drugs for 40 h after transfection and JEG-3 cells were treated as indicated in the figure. The plasmid pFN-CAT 
contains ",1.6 kb of human FN gene 5' flanking sequence. It also contains ~1.1 kb of DNA from the original charon 28 ~,-phage vector. 
This phage DNA does not seem to affect induction of the FN promoter since similar results have been obtained with a vector containing 
only 520 bp of FN 5' flanking sequence and no phage DNA (data not shown). In addition,  when the FN promoter,  including the phage 
DNA is cloned in the opposite orientation,  CAT activity is greatly reduced  (unpublished data). 
FN, the combination of drugs results in induction indicating 
some potential overlap in  the  induction  pathways of these 
drugs. 
Discussion 
In  this  study  we  examined how  FN  is  regulated  by three 
different  drugs:  the  synthetic  glucocorticoid,  dexametha- 
sone; forskolin, which elevates adenylate cyclase levels; and 
TGF-13. The effect of these drugs on FN biosynthesis varies 
with cell type. 
In ceils in  which FN  biosynthesis is stimulated by glu- 
cocorticoids,  this  effect  appears  to  be  mediated  through 
the glucocorticoid receptor (Oliver et al.,  1983);  however, 
the  presence  of the  glucocorticoid  receptor  alone  is  not 
sufficient for FN induction since TE671 cells contain gluco- 
corticoid receptors which translocate to the nucleus (Dean, 
D. C., R. F. Newby, and S. Bourgeois, unpublished results) 
but  FN  biosynthesis  in  these  ceils  does  not  respond  to 
glucocorticoids.  This  is  not  surprising  since  the  effect of 
glucocorticoids on FN biosynthesis is indirect and appears 
to involve selective stabilization of FN mRNA. Protein syn- 
thesis is required for this effect, therefore, a protein(s) is be- 
ing synthesized in response to dexamethasone which is capa- 
ble of either directly or indirectly  stabilizing FN  mRNA. 
The nature of such a  protein,  as well as the region of FN 
mRNA required for this effect, may provide insight into the 
mechanism involved. A  similar effect of glucocorticoids on 
the  stability of human  growth hormone has  been demon- 
strated (Pack and Axel, 1987). These authors suggested that 
this increase in growth hormone mRNA half-life is due to a 
glucocorticoid-induced lengthening of the poly A tail on the 
mRNA. 
The rate of FN biosynthesis is also affected by cAMP and 
drugs such as forskolin which raise cellular levels of cAMP. 
In both HT-1080 cells and the choriocarcinoma cell, JEG-3, 
forskolin produces a  significant increase in the rate of FN 
biosynthesis. The induction in both cell lines seems to result, 
at least in part, from an increase in the rate of FN gene tran- 
scription;  however, the mechanisms appear to be different. 
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Figure 8. Effect of TGF-13 on the kinetics of the rate of FN biosyn- 
thesis  in HT-1080 and WI38 cells  lines.  Cells  were treated  with 
TGF-I~ (see  Fig.  1)  for  the  indicated  times  and  labeled  with 
[35S]methionine. FN was then immunoprecipitated  and subjected 
to electrophoresis on an SDS-polyacrylamide gel.  The FN band 
was cut from the gel and the number of cpm in each band was deter- 
mined. 
In JEG-3 cells, a rapid induction is observed, which begins 
to  decrease  after  24  h  suggesting  some  type of feedback 
mechanism.  Forskolin induction in these cells seems to be 
entirely due to a transcriptional effect which does not require 
protein synthesis. This is similar to the mechanism observed 
for cAMP induction of somatostatin (Montminy et al.,  1986), 
proenkephalin  (Comb et  al.,  1986),  phosphoenolpyruvate 
carboxy-kinase  (Short  et  al.,  1986),  vasoactive  intestinal 
polypeptide  (Tsukada  et  al.,  1987),  and  the  ct-subunit  of 
chorionic  gonadotropin  (Silver  et  al.,  1987).  The  cAMP 
effect on these genes is rapid, transcriptional, and insensitive 
to cycloheximide (Cimbala et al.,  1982). It has been demon- 
strated that the DNA sequence-TGACGTCA-is  the core 
of a cAMP response element (CRE) found in the 5'-flanking 
region of cAMP-responsive genes (Short et al.,  1986; Silver 
et al.,  1987; Montminy and Bilezikjian,  1987) and that this 
sequence binds to a 43-kD nuclear protein (Montminy and 
Bilezikjian,  1987). We find two potential CRE sequences in 
the FN promoter (-170 and -415) that bind nuclear proteins 
and we have demonstrated that a 25-bp oligonucleotide con- 
raining one of these sequences (-170) is sufficient to confer 
inducibility on an exogenous promoter (Dean et al.,  1987; 
Dean, D. C., M. S. Blakeley, R. E  Newby, and S. Bourgeois, 
manuscript in preparation).  The effect of cAMP could be to 
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Figure 9. Effect of FCS on the rate of FN biosynthesis  in HT-1080 
cells. Cells were incubated in the presence or absence of serum and 
with or without TGF-13 (500 pm) as indicated in the figure for 48 h. 
The amount of FN was quantitated  as in Figs. 8 and 10 and Table 
I. The striped bars represent  cells incubated with no added TGF-13, 
while the open bars represent  cells  incubated  in the presence of 
TGF-13. The numbers given above the bars are multiples  of the in- 
duction rate of FN. 
induce  the  synthesis  of the  43-kD  nuclear  protein  which 
binds to the CRE (Montminy and Bilezikjian,  1987); how- 
ever, we see no apparent difference in the amount of nuclear 
protein that binds to the FN CRE (as analyzed by DNase I 
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Figure 10.  Kinetics of the forskolin-induced  increase  in the rate or 
FN biosynthesis in HT-1080 and JEG-3 cell lines. The concentra- 
tion of forskolin  (forskolin  and IBMX) is given in Fig.  1 and the 
experimental  procedure is similar to that  in Fig.  8. 
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D. C., R. E  Newby, and S. Bourgeois, unpublished results). 
There is evidence that cAMP treatment results in phosphory- 
lation of this protein (Montminy and Bilezikjian, 1987) which 
could stimulate its effect on gene transcription. 
The cAMP induction of FN in the fibrosarcoma cell line 
(HT-1080)  occurs through a different mechanism than in the 
JEG-3 cells. In these cells, protein synthesis is required for 
cAMP induction and the response time is >24 h. It will be 
of interest to determine if the transcriptional aspect of cAMP 
induction in the fibrosarcoma cells is modulated through a 
CRE or some other DNA sequence. 
Induction of FN by "IGF-13  in fibroblasts seems to be rapid 
and does not require protein synthesis. This is consistent 
with previous results (Ignotz and Massague,  1985; Ignotz 
and Massague,  1986; Ignotz et al.,  1987). Transfection ex- 
periments done in our study demonstrate that TGF-13 induc- 
tion of FN in fibroblasts is transcriptional and is mediated 
through FN promoter sequences. TGF-13 binds to three dis- 
tinct types of receptors, however, the detailed mechanism of 
how induction occurs is unknown (Cheifetz et al., 1986). It 
will  be  of interest to  determine which  FN  promoter  se- 
quences and nuclear proteins are required for TGF-13 induc- 
tion. This should provide insight into the mechanism of TGF- 
13 induction. 
As demonstrated with forskolin, TGF-I~ induction of FN 
in the fibrosarcoma cells (HT-1080)  occurs through a differ- 
ent mechanism than in fibroblasts. The kinetics of TGF-13 in- 
duction are similar to those of forskolin induction in these 
cells and, as with forskolin, protein synthesis is required for 
the effect. Since the FN promoter mediates induction of FN 
by TGF-13 in both fibrosarcoma (HT-1080)  and fibroblast 
cells, it is of interest to compare the DNA sequences required 
for this induction in these cell lines. 
The synergism between glucocorticoids and either forsko- 
lin or TGF-13 in the fibrosarcoma cells produces very large 
increases in the level of FN and FN mRNA which seems to 
result from the combination of a transcriptional effect (for- 
skolin and TGF-13) and an mRNA stabilization effect (glu- 
cocorticoids). A similar mechanism seems to account for the 
synergistic effect of thyroid hormone (transcriptional) and 
glucocorticoid (mRNA stabilization and transcriptional) on 
the growth hormone gene (Paek and Axel, 1987). Synergism 
between cAMP and glucocorticoids has also been observed 
with  phosphoenolpyruvate  carboxykinase  (Krone  et  al., 
1976), preproenkephalin (Yoshikawa and Sabol, 1986), tyro- 
sine aminotransferase (Meyer and Morris,  1986), and glyc- 
erol-3-phosphate dehydrogenase (Meyer and Morris, 1986). 
Results of the induction of FN by all three drugs in lung 
and foreskin fibroblasts are very similar and are probably 
representative of the type of FN regulation occurring in nor- 
mal fibroblasts. In the fibrosarcoma cells, the basal level of 
FN is greatly decreased (',o50-fold),  which correlates with 
a decrease in FN mRNA half-life. Dexamethasone treatment 
increases FN mRNA half-life in HT-1080 to a level similar 
to that in fibroblasts. It is also possible that TGF-13 and for- 
skolin increase FN mRNA stability in these cells although 
not to the degree that dexamethasone does. Direct measure- 
ments of mRNA half-life will be required to support this hy- 
pothesis. It has been demonstrated that HT-1080 cells con- 
tain a mutant N-ras gene which is active in transformation 
assays (Brown et al., 1984). Since activated members of the 
ras gene family decrease the amount of FN and collagen (I) 
when transfected into cells (Liau et al,, 1985; Sistonen et al., 
1987) it is tempting to speculate that this inhibition results, 
at least in part, from an activated N-ras-mediated destabili- 
zation of FN mRNA and that each of these drugs causes the 
synthesis of some protein(s) which directly or indirectly in- 
creases FN mRNA half-life. Since the ras family of proteins 
is cytoplasmic, a cascade of events appears to be necessary 
for ras proteins to exert effects in the cell nucleus (reviewed 
by Marshall, 1987). The action of the drugs in HT-1080 cells 
could be either on a step in the cascade between the ras pro- 
tein and the nucleus or on steps which occur after an initial 
set of proteins are induced. 
It seems likely that the individual pathways for induction 
with TGF-13 and forskolin are the same in HT-1080 as in 
other cells. The requirement of protein synthesis for induc- 
tion with both drugs in HT-1080 may indicate that a compo- 
nent(s) normally present in these pathways is suppressed as 
a  result of this particular transformed phenotype and that 
synthesis of such a protein(s) is required before a direct tran- 
scriptional effect can occur. Inhibition of the cAMP pathway 
when cells are transfected with an activated ras gene has been 
previously demonstrated (Tarply et al., 1986). Identification 
of any such protein(s) may provide insight into the mecha- 
nism involved in transformation by the ras gene family as 
well as assist in determining the pathway of TGF-13 induction 
and clarifying any overlap with the cAMP pathway. 
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